Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
La Jolla Pharmaceutical Company
Waltham, Massachusetts, United Stateslajollapharmaceutical.com ↗
- Ownership
- Public · LJPC
- Employees
- ~61
- Development stage
- Other
01
Overview
La Jolla Pharmaceutical Company commercializes GIAPREZA (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) for treating complicated intra-abdominal infections. The company reported $10.4 million in net product sales for Q1 2022, up 21% from the same period in 2021[3].
- Therapeutic areas
- HematologyCardiovascularInfectious Diseases
- Modalities
- PeptidesSmall moleculesAntibiotics
- Industry
- Biotech
02
Partnerships
PAION UK LTDTetraphase Pharmaceuticals
Beyond the preview
Go deeper on La Jolla Pharmaceutical Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on La Jolla Pharmaceutical Company.